Bosentan: Is There a Role in IPF? : Clinical Pulmonary Medicine

Home > May 2008 - Volume 15 - Issue 3 > Bosentan: Is There a Role in IPF?

< Previous Abstract | Next Abstract >

Text sizing:

Clinical Pulmonary Medicine:

May 2008 - Volume 15 - Issue 3 - pp 181-182

doi: 10.1097/CPM.0b013e3181729d67

Pulmonary Trends

Bosentan: Is There a Role in IPF?

Shalshin, Alex MD; Spiegler, Peter MD

Abstract

Synopsis: Use of bosentan in patients with idiopathic pulmonary fibrosis demonstrated no improvement in exercise tolerance; however, there was a suggestion of delayed time to death or disease progression.

Source: King TE, Behr J, Brown KK, et al. BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177:75-81.

You currently do not have access to this article.

You may need to:

Register an account.
Login if you are a registered subscriber.
Subscribe to this Journal , or
Purchase access to this article if you are not a current subscriber.
View this article in Ovid if your institution subscribes to this journal.

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

NEW! Mobile View

Article Tools

You currently do not have access to this article.

You may need to:

Register an account.
Login if you are a registered subscriber.
Subscribe to this Journal , or
Purchase access to this article if you are not a current subscriber.
View this article in Ovid if your institution subscribes to this journal.

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Home	Current Issue	Previous Issues	For Authors	Journal Info